Create issue ticket

201 Possible Causes for 0, HCL, Topotecan

Show results in: 日本語

  • Idarubicin

    10mg 203 2018-11-13 Buy Sigma-Aldrich 1335701 Idarubicin 57852-57-0 50mg 1080.45 2018-11-20 Buy Cayman Chemical 14176 Idarubicin (hydrochloride) 98% 57852-57-0 1mg 28 2018[] Hydrochloride Synonyms: (7S,9S)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione Hydrochloride; 4-DMD HCl[] Fluorouracil ) Gemcitabina (Gemzar ) Ifosfamida (Tronoxal ) Irinotecan (Campto ) Melfalan (Melfalan ) Metotrexato (Metotrexato ) Pemetrexed (Alimta ) Rituximab (Mabthera ) Topotecan[]

  • Small Cell Carcinoma of the Lung

    Small cell carcinoma of the breast and small cell carcinoma of the lung patients had similar patterns of other immunohistochemical expression (0 v 0 % PDL1, 50 v 42 % PD1,[] This case demonstrates that hairy cell leukemia may be responsive to combination regimens.[] Huber RM, Gatzemeier U, Gosse H et al (2000) Topotecan in second-line therapy of SCLC: Impact on survival? Onkologie 23 (suppl 3):9–12 15.[]

  • Daunorubicin

    Invasive fungal disease (41.6% vs. 0%; P .012), creatinine elevation (P .001), abdominal pain (33% vs. 0%; P .033), and need for intensive care unit admission (33.3% vs. 0%[] HCL Alpharma interactions Daunorubicina HCL Alpharma side effects Daunorubicina HCL Alpharma contraindications What is Daunorubicina HCL Alpharma?[] Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined.[]

  • Gemcitabine

    CASE REPORT: A metastatic pancreatic cancer was diagnosed in a 60-year-old patient with a performance status of 0.[] , HCl, 4-Amino-1-((2 R ,5 S )-3,3-difluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one, HCl Primary Target: DNA Overview Supporting Documentation Overview Key[] […] cefazolin, chlorproazine, cimetidine, clindamycin, cytarabine, diphenhydramine, dopamine, etoposide, heparin, linezolid, metoclopramide, morphine, paclitaxel, KCl, NaHCO3, topotecan[]

  • Irinotecan

    In Patient 3, lobar embolization of the target lesion in segment II resulted in 0% viability.[] HCl Trihydrate manufacturer order Irinotecan HCl Trihydrate Irinotecan HCl Trihydrate distributor[] […] activity than both topotecan and irinotecan in NCI-H1048 tumors that had progressed on previous carboplatin plus etoposide treatment.[]

  • Antineoplastic Agent

    In contrast, in NIH-3T3 cells, taurolidine exposure did not increase DNA debris in the sub-G(0)/G(1) region.[] At a 25% w/v concentration of RDM-beta-CD, the solubility of CPT was 228.45 /- 8.45 microg/ml, about 171 times higher than that in 0.02 N HCl.[] CONCLUSIONS: Topotecan is an effective second-line agent for patients with unresponsive or relapsed cancer of the ovary.[]

  • Doxorubicin

    RESULTS: CREB3L1 expression levels in TNBC responsive to doxorubicin-based chemotherapy (RCB class 0-2) were significantly higher than that in resistant cancers (RCB class[] Product Specifications Doxorubicin HCl, USP Grade Formula: C 27 H 29 NO 11 HCl MW: 579.98 g/mol Storage/Handling: Store desiccated at 2-8 C.[] Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer . J Clin Oncol 1999 ; 17 : 658 – 667 .[]

  • Etoposide

    Etoposide, CAS 33419-42-0, is cell-permeable inhibitor of topoisomerase II inhibitor (IC50 59.2 µM). Displays anti-tumor activity.[] The pH was adjusted to 4.20 with 0.2-N HCl. Mobile phase was used after degassing.[] Most patients (77.5%) received cisplatin plus etoposide as first-line therapy, and camptothecins such as irinotecan or topotecan as second-line therapy.[]

  • Topotecan

    67, 90% CI 0·51-0·88; p 0·0079).[] Abstract Topotecan HCl is an antitumor drug exhibiting topoisomerase 1-inhibitory activity.[] Administration of topotecan down-regulates its target, topoisomerase-I; therefore, it is dosed to maximize efficacy and minimize related toxicity. [17] Topotecan is often[]

  • Filgrastim

    Overall difference in DSN between reference and biosimilar medicines was not statistically significant (0·06 d [95% CI -0·05, 0·17]).[] We also included chronic lymphocytic leukemia (CLL), hairy cell leukemia and multiple myeloma.[] Four patients had a disease progression date more than 6 months after the start of veliparib-topotecan therapy.[]